ERBB2 and neoplasm: Detailed statistical analyses of the CD4 + and CD8 + positive rates demonstrated that the HER2-CXCR5-CCR6-CAR T group had infiltration rates of 5.4% for CD4 + CAR T and 8.8% for CD8 + CAR T cells in the tumor tissue.